• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

勘误：靶向JUN、CEBPB和HDAC3：克服缺氧性胶质母细胞瘤耐药性的新策略。

Corrigendum: Targeting JUN, CEBPB and HDAC3: a novel strategy to overcome drug resistance in hypoxic glioblastoma.

作者信息

Gao Yixing, Liu Bao, Feng Lan, Sun Binda, He Shu, Yang Yidong, Wu Gang, E Guoji, Liu Chang, Gao Yuqi, Zhang Erlong, Zhu Bo

机构信息

Department of Oncology, Xinqiao Hospital, Army Medical University, Chongqing, China.

Institute of Medicine and Equipment for High Altitude Region, College of High Altitude Military Medicine, Army Medical University, Chongqing, China.

出版信息

Front Oncol. 2024 Apr 23;14:1392899. doi: 10.3389/fonc.2024.1392899. eCollection 2024.

DOI:10.3389/fonc.2024.1392899
PMID:38715787
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11075629/
Abstract

[This corrects the article DOI: 10.3389/fonc.2019.00033.].

摘要

[本文更正了文章的数字对象标识符：10.3389/fonc.2019.00033。]

相似文献

1
Corrigendum: Targeting JUN, CEBPB and HDAC3: a novel strategy to overcome drug resistance in hypoxic glioblastoma.勘误：靶向JUN、CEBPB和HDAC3：克服缺氧性胶质母细胞瘤耐药性的新策略。
Front Oncol. 2024 Apr 23;14:1392899. doi: 10.3389/fonc.2024.1392899. eCollection 2024.
2
Corrigendum: Targeting JUN, CEBPB, and HDAC3: A Novel Strategy to Overcome Drug Resistance in Hypoxic Glioblastoma.勘误：靶向JUN、CEBPB和HDAC3：克服缺氧性胶质母细胞瘤耐药性的新策略。
Front Oncol. 2020 Apr 28;10:644. doi: 10.3389/fonc.2020.00644. eCollection 2020.
3
Targeting JUN, CEBPB, and HDAC3: A Novel Strategy to Overcome Drug Resistance in Hypoxic Glioblastoma.靶向JUN、CEBPB和HDAC3：克服缺氧性胶质母细胞瘤耐药性的新策略。
Front Oncol. 2019 Feb 1;9:33. doi: 10.3389/fonc.2019.00033. eCollection 2019.
4
Corrigendum: Mifepristone as a Potential Therapy to Reduce Angiogenesis and P-Glycoprotein Associated With Glioblastoma Resistance to Temozolomide.勘误：米非司酮作为一种潜在疗法，用于降低与胶质母细胞瘤对替莫唑胺耐药相关的血管生成和P-糖蛋白水平。
Front Oncol. 2021 Mar 22;11:675806. doi: 10.3389/fonc.2021.675806. eCollection 2021.
5
Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells.通过 COP1/c-Jun/HDAC3 轴增强 PD-L1 启动子上的组蛋白 H3 乙酰化对于耐药癌细胞中 PD-L1 的表达是必需的。
J Exp Clin Cancer Res. 2020 Feb 5;39(1):29. doi: 10.1186/s13046-020-1536-x.
6
Corrigendum: Salivary Gland Carcinoma: Novel Targets to Overcome Treatment Resistance in Advanced Disease.勘误：唾液腺癌：克服晚期疾病治疗耐药性的新靶点。
Front Oncol. 2021 Apr 9;11:669486. doi: 10.3389/fonc.2021.669486. eCollection 2021.
7
Corrigendum: The Prognostic and Therapeutic Potential of LRIG3 and Soluble LRIG3 in Glioblastoma.勘误：LRIG3和可溶性LRIG3在胶质母细胞瘤中的预后及治疗潜力
Front Oncol. 2020 Sep 25;10:591112. doi: 10.3389/fonc.2020.591112. eCollection 2020.
8
Corrigendum: Machine Learning-Based Analysis of Magnetic Resonance Radiomics for the Classification of Gliosarcoma and Glioblastoma.勘误：基于机器学习的磁共振影像组学分析用于胶质肉瘤和胶质母细胞瘤的分类
Front Oncol. 2021 Oct 18;11:774369. doi: 10.3389/fonc.2021.774369. eCollection 2021.
9
Corrigendum: MELK Inhibition Effectively Suppresses Growth of Glioblastoma and Cancer Stem-Like Cells by Blocking AKT and FOXM1 Pathways.勘误：MELK抑制通过阻断AKT和FOXM1信号通路有效抑制胶质母细胞瘤和癌症干细胞样细胞的生长。
Front Oncol. 2022 Apr 22;12:911817. doi: 10.3389/fonc.2022.911817. eCollection 2022.
10
Corrigendum: PHF20 promotes glioblastoma cell malignancies through a -dependent pathway.勘误：PHF20 通过 α 依赖途径促进胶质母细胞瘤细胞恶性增殖。
Front Oncol. 2023 Mar 22;13:1157694. doi: 10.3389/fonc.2023.1157694. eCollection 2023.